The global viral vector and plasmid DNA manufacturing market size is calculated at USD 8.66 billion in 2025 and is expected ...
Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® ...
AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
Accurate monitoring of particle size and growth is essential to ensure scalability in the development of transfection vectors ...
Applied DNA Sciences, Inc. (NASDAQ: APDN) Q1 2025 Earnings Call Transcript February 13, 2025 Applied DNA Sciences, Inc. misses on earnings expectations. Reported EPS is $-0.56 EPS, expectations were $ ...
BI 3720931 is a first-in-class, inhaled lentiviral vector-based gene therapy that could potentially address unmet needs by inserting a functional copy of the CFTR gene in the DNA of airway epithelial ...